Wisconsin Alumni Research Foundation

Gist-Brocades N.v.

Igene Biotechnology, Inc.

University of California

The Medical College of Wisconsin, Inc.

Gist-Brocades B.v.

S.s. Steiner, Inc.

Authorize.net LLC

Lightbridge Corporation

Other

The Scripps Research Institute

Dsm N.v.

Mcw Research Foundation, Inc.

Spa Societa Prodotti Antibiotici S.p.a.

Michael Foods, Inc.

Eric Arthur Johnson

Marite Bradshaw

William Howard Tepp

Sabine Pellett

Michael C Goodnough

Joseph T Barbieri

Ib Christensen

Robert Larsen

Steffen Radich Johansen

Bent Fleno Slashed

Mark J Handzel

Kristin M Marshall

David James Beebe

Huei-hsiung Yang

Kwok P Ho

Michael Baldwin

Beril Geldiay-Tuncer

William T Hall

David Schreiber

Carl J Malizio

Nicholas Lawrence Abbott

Gary E Borodic

Gerhard J Haas

Tony L Yaksh

Ernani Dell'Acqua

Qinghao Xu

Guangyun Lin

Marc Marino

Amanda Przedpelski

Sarah Teren

Joon-Seo Park

Christina Pier

Raymond C Stevens

Lorenzo Ferrari

Howard Kaushansky

Dena Lyras

Christina L Pier

William H Tepp

Sunil Prakash

Martin Brunecky

Eileen M McGrath-Hadwen

Julian I Rood

Hiroshi Sugiyama

Regina Clare Meyer Whitemarsh

Amy Paguirigan

Regina Whitemarsh

June F Parreiras

Michael D Liss

Flemming B Jensen

Mark Joseph Jacobson

Bent Fleno

Pal Erik Gustav Stenmark

Byron F Brehm-Stecher

Alan B Scott

Regina Clare Whitemarsh

Brian P Makare

Huei-Hsiung Yang

Provided herein are antigenic peptides comprising the SARS-COV-2 spike protein receptor binding domain (CRBD) polypeptide or portions thereof, linked to a non-catalytic, non-toxic tetanus toxin variant (i.e., a modified tetanus toxin or 'MTT') and vaccine compositions comprising the same. In addition, provided herein are methods for making and using CRBD-MTT fusion proteins as immunogenic agents.

COVID-19 vaccine

Provided herein are engineered non-catalytic, non-toxic tetanus toxin variants and methods of using such engineered tetanus toxin variants as low dose, protective vaccines that are non-toxic and more potent than their respective chemically inactivated toxoids. In addition, provided herein are conjugate vaccine carriers comprising engineered tetanus toxin variants and methods of using such conjugate vaccines to elicit T-cell dependent immune memory responses which can target a broad spectrum of microbial pathogens as a single vaccine.

Modified clostridial neurotoxins as vaccines and conjugate vaccine platforms

The present disclosure relates to neurotoxins and uses thereof. In particular, provided herein are botulinum neurotoxins with altered properties and uses thereof (e.g., research, screening, and therapeutic uses).

Neurotoxins and uses thereof

The present disclosure relates to chimeric neurotoxins and uses thereof. In particular, provided herein are chimeric botulinum neurotoxins with altered properties and uses thereof (e.g., research, screening, and therapeutic uses).

Hybrid neurotoxins and uses thereof

A mutant strain of the bacteriumhaving an inactivated botulinal neurotoxin gene is disclosed. The mutant strain contains an artificially created and inserted modified intron vector between nucleotides 580 and 581 of the sense strand of the gene. The mutant strain can be used in microbiological challenge testing of foods and food processing methods.

[object Object]

A chimeric toxin is disclosed comprising a peptide ligand specifically targeting neurons involved in pain processing; and a clostridial neurotoxin light chain, wherein the ligand is linked to the light chain. The methods of preparing such chimeric toxin and the method of using the chimeric toxin to regulate pain transmission are also disclosed.

Regulation of specific spinal neurons regulating pain transmission via chimeric toxins

The present invention provides novelconjugatively transmissible plasmids and methods of use thereof. Specifically, described herein are novel, conjugatively transmissible clostridial plasmids which are capable of being transferred among and between clostridial species. The novel plasmids of the present invention therefore permits the delivery of heterologous clostridial genes into a clostridial host, such as, and the expression of genes of interest in that host, including clostridial toxins and the nontoxigenic components of the toxin complex, toxin fragments, or antigenic portions thereof, in a way both that ensures abundant expression and facilitates purification. Furthermore, toxins with altered structures, chimeric, hybrid toxins, and other toxin derivatives valuable in medicine could be synthesized in this system.

Conjugative plasmids and methods of use thereof

Preparations ofneurotoxin BoNT/A3 and methods for using such preparations for treating a patient having a symptom in need of botulinum toxin therapy are provided herein.

Purification, characterization, and use of Clostridium botulinum neurotoxin BoNT/A3

The present invention provides a novel isolated plasmid, wherein the plasmid is a native plasmid found in uniquetype A strains and encode either BoNT/A3 or BoNT/A4 and BoNT/B. The present invention also provides a method of obtaining a plasmid-encoded botulinum neurotoxin and botulinum neurotoxin complex comprising the step of isolating a plasmid encoding the cntA/A or cntA/B neurotoxin gene and genes encoding protein components of the toxin complex from atype A strain. The inventors performed comparative analyses of representative BoNT/A subtype strains by pulsed-field gel electrophoresis (PFGE) and Southern hybridizations with probes specific for the BoNT/A and B genes, cntA/A and cntA/B. Unexpectedly, the inventors determined that the genes encoding BoNT/A3 in the A3 strain, and BoNT/A4 and BoNT/B in the A4 strain, are on plasmids.

The present invention relates to compositions and methods for testing agents (e.g.,neurotoxin (BoNT) detection and analysis). In particular, the present invention relates to the use of Human induced pluripotent stem (hiPS) derived cells for agent detection and analysis.

Compositions and methods for toxigenicity testing

A highly sensitive method of analyzing a sample for the presence or activity of botulinum neurotoxin (BoNT) or antibodies specific for botulinum neurotoxin is disclosed. In one embodiment, the method comprises the steps of preparing primary non-human mammalian or avian spinal cord cells, and exposing the cells to a test sample, in parallel with a control sample, and examining the extent of cleavage of the intracellular neuronal target protein in both the test and control sample.

Method of detecting botulinum neurotoxin and antibodies that neutralize botulinum neurotoxin action

Differentiated cholinergic cells having motor neuron-like morphology and increased sensitivity to botulinum neurotoxin are provided herein. Methods of using such differentiated cells for detecting neurotoxin are also provided.

Compositions and methods of using differentiated cells sensitized to botulinum neurotoxin

A novel subtype of type A botulinum neurotoxin (BoNT/A) is disclosed in the application. Methods to purify the neurotoxin as well as uses thereof are also disclosed.

The present invention provides a novel isolated plasmid, wherein the plasmid is a native plasmid found in uniquetype A strains and encode either BoNT/A3 or BoNT/A4 and BoNT/B. The present invention also provides a method of obtaining a plasmid-encodedneurotoxin andneurotoxin complex comprising the step of isolating a plasmid encoding the cntA/A or cntA/B neurotoxin gene and genes encoding protein components of the toxin complex from atype A strain. The inventors performed comparative analyzes of representative BoNT/A subtype strains by pulsed-field gel electrophoresis (PFGE) and Southern hybridizations with probes specific for the BoNT/A and B genes, cntA/A and cntA/B. Unexpectedly, the inventors determined that the genes encoding BoNT/A3 in the A3 strain, and BoNT/A4 and BoNT/B in the A4 strain, are on plasmids.

Growing community of inventors

Madison, WI, United States of America

Eric Arthur Johnson